期刊文献+

PLA表位肽免疫微球诱导CTL对肝癌细胞的杀伤作用

Polylatic acid microspheres-induced CTL cytotoxicity against hepatocellular carcinoma cell lines
下载PDF
导出
摘要 目的:考察两种载肽聚乳酸((polylatic acid,PLA)免疫微球M1(hAFP158~166)和M2(hAFP218~226)在体外诱导特异性CTL的能力及其对肝癌细胞的杀伤作用。方法:制备分别荷载表位肽hAFP158~166、hAFP218~226的PLA免疫微球M1和M2,体外刺激HLA—A2^+健康志愿者的外周血单个核细胞(PBMC)作为效应细胞,实验分为3组:对照组、hAFP表达组和hAFP阴性组。采用标准^(51)Cr释放法检测CTL杀伤活性。结果:两种免疫微球在体外均能刺激人PBMC增殖,形成大量可见克隆;两者诱导的效应细胞对hAFP^+的荷肽他细胞、HepG-2和Alexander的杀伤率均达75%以上,均显著高于不表达hAFP的膀胱癌细胞BTT和未荷肽的他细胞,差异非常显著(P<0,01),而两者杀伤活性之间没有明显差异(P>0.05)。结论:两种载肽聚乳酸免疫微球均能在体外诱导产生特异性CTL,并对表达靶抗原的肝癌细胞有较强杀伤作用。 Objective: To investigate the in vitro efficiency of two kinds of polylatic acid (PLA) immunomicrospheres :M1 ( hAFP158 ~ 166 ) and M2 ( hAFP218 ~ 226) in specific inducement of CTL and the cytotoxicity of CTL against hepatocellular carcinoma ceils. Methods: Pripheral blood monocytes (PBMC) of HLA-A2 healthy volunteers stimulated in vitro by peptide-loading microspheres were taken as effectors. The experiments were divided into three groups: control group, hAFP^+ tumor ceils group, and hAFP- tumor ceils group. The specific cytolysis of target ceils was assessed by ^(51)Cr-release assay. Results: Both M1 and M2 induced proliferation of HLA-A2^+ PBMC, forming visible clones. The effector ceils induced by M1 and M2 both had an cytolysis rate over 75% for hAFP^+ tumor ceils, which was significantly higher than that for hAFP-tumor cells (P〈0. 01 ). But there was no significant difference in cytolysis rate concerning the two kinds of microspheres (P〉0. 05 ). Conclusion: The two kinds of microspheres can both induce specific CTL in vitro, which can effectively kill hAFP^+ tumor ceils.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2006年第3期167-170,共4页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(N0.30070855)
关键词 肝癌细胞 聚乳酸微球 AFP CTL表位肽 Hepatocellular carcinoma cell PLA microspheres AFP CTL epitope peptide
  • 相关文献

参考文献2

二级参考文献17

  • 1Melief CAM, Kast WM. Lessons from T cell responses to virus - induced tumors for cancer eradication in general[J]. Cancer Surv, 1992, 13:81 --89.
  • 2Ruiz- Cabello F, Garrido F. HLA and cancer:from research to clinical impact[J].Immunol Today, 1998, 19(12):539-542.
  • 3Cromme F V, Airey J, et al. Loss of transporter protein, encoded by the TAP - 1 gene, is highly correlated with loss of HLA expression in cervical carcinomas[J]. J Exp Med, 1994, 179:335-340.
  • 4Sung CH, Hu CP, et al. Expressian of class Ⅰ and class Ⅱ major histocompatibility antigens an human hepatocellular carcinoma[J]. J Clin Invest, 1989,83(2) :421 - 427.
  • 5Wadee AA, Paterson A, et al. HLA expression in hepatocellular carcinoma lines[J]. Clin Exp Immunol, 1994, 97(2):328-33.
  • 6Kurokohchi K, Cairrington M, et al. Expression of HLA class Ⅰ molecules and the transporter associated with antigen processing in hepatocellular carcinoma[J] .Hepatology,1996, 23(5):1181 - 1188.
  • 7Butterfield LH, Meng WS, et al. T cell responses to HLA- A^* 0201 -restricted peptides derived from human α fetoprotein[J]. J Immunology,2001,166:5300 - 5308.
  • 8Paroli M,Carloni G,Franco A,De Petrillo G,Alfani E,Perrone A,Barnaba V.Human hepatoma cells expressing MHC antigens display accessory cell function,dependence on LFA-1/ICAM-1 interaction[].Immunology.1994
  • 9Ruiz-Cabello F,Garrido F.HLAand cancer:Fromresearch to clinical impact[].Immunology Today.1998
  • 10Sung CH,Hu CP,Hsu HC,Ng AK,Chou CK,Ting LP,Su TS,Han SH,Chang CM.Expression of class Ⅰ and class Ⅱ major histocompatibility antigens on human hepatocellular carcinoma[].The Journal of Clinical Investigation.1989

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部